Cargando…
Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non‐interventional study MabSCale
BACKGROUND: Rituximab has become a standard treatment for non‐Hodgkin lymphoma. Clinical studies have demonstrated the efficacy of rituximab in combination with standard chemotherapies in the treatment of follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL) patients. This non‐intervent...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939131/ https://www.ncbi.nlm.nih.gov/pubmed/36017743 http://dx.doi.org/10.1002/cam4.5160 |